Table 1.
Demographic and clinicopathological characteristics of patients undergoing a major hepatectomy from 2000–2012 (n = 719)
| Variable | N (%) or median [range] |
|---|---|
| Gender, male | 298 (41%) |
| Race | |
| White | 467 (65%) |
| Black | 164 (23%) |
| Other | 88 (12%) |
| Age, median [range], years | 57 [18–88] |
| BMI, median [range], kg/m2 | 26.4 [16.6–57.8] |
| ASA Class | |
| 2 | 229 (32%) |
| 3 | 463 (64%) |
| 4 | 20 (3%) |
| Hepatitis B | 18 (3%) |
| Hepatitis C | 20 (3%) |
| Smoking history, >10 pack-years | 217 (30%) |
| Alcohol abuse | 44 (6%) |
| Cancer diagnosis (indication for hepatectomy) | 519 (72%) |
| Platelet count, median [range], × 103/ml | 241 [69–900] |
| Albumin, median [range], gm/dl | 3.6 [1.3–4.7] |
| Total bilirubin, median [range], mg/dl | 0.6 [0.1–24.6] |
| INR, median [range] | 1.00 [0.81–2.61] |
| Portal vein embolization | 30 (4%) |
| Resection type | |
| Extended left | 41 (6%) |
| Extended right | 143 (20%) |
| Left hemihepatectomy | 163 (23%) |
| Right hemihepatectomy | 279 (39%) |
| Central hepatectomy | 17 (2%) |
| Non-anatomic | 76 (10%) |
| Bile duct resection | 143 (20%) |
| EBL, median [range], ml | 400 [50–5900] |
| Intra-operative transfusion | 184 (26%) |
| Pathology | |
| Metastatic colorectal cancer | 229 (32%) |
| Hepatocellular carcinoma | 69 (9%) |
| Cholangiocarcinoma | 88 (12%) |
| Metastatic NET | 34 (5%) |
| Other | 299 (42%) |
| Cirrhosis | 26 (4%) |
| Steatosis | 207 (29%) |
| Any complication | 443 (61.6%) |
| Major complications (Grade III–V) | 169 (23.5%) |
| Post-operative hepatic insufficiency (PHI) | 63 (8.8%) |
| 30-day mortality | 29 (4.0%) |
| 90-day mortality | 39 (5.4%) |
ASA, American Society of Anesthesiology; BMI, body mass index; EBL, estimated blood loss; INR, international normalized ratio; NET, neuroendocrine tumour.